<DOC>
	<DOCNO>NCT00544518</DOCNO>
	<brief_summary>Objective -- - Benfluorex may effect glucose control type 2 diabetes improves hyperlipidemia . We seek compare impact benfluorex versus metformin glucose control insulin secretion Chinese type 2 diabetic patient . Research design methods— -- 16-week , double-blind , multiple center , random parallel control study design compare impact benfluorex ( 150-450mg/day , provide Shandong Xinhua Pharmaceutical Company Limited China ) glucose control , insulin secretion safety metformin type 2 diabetic patient . 240 type 2 diabetic patient recruit receive benfluorex metformin ( 1:1 ) . HbA1c , plasma lipid level , insulin glucose 0 ' , 30 ' , 120 ' standard meal measure treatment , fast postprandial glucose measure 4 time regularly . The change HbA1c baseline end treatment take main efficacy criterion , change fast standard meal glucose insulin level plasma lipid level take secondary criterion . All patient give safety monitor prior post treatment . Data management statistical analysis adopt DAS Clinical Trial 2.0 .</brief_summary>
	<brief_title>Impact Benfluorex Versus Metformin Glucose Control Insulin Secretion Chinese Type 2 Diabetic Patients</brief_title>
	<detailed_description>During whole study , patient meet physician regular basis . Safety assess adverse event spontaneous reporting、physical examination、recording vital signs、laboratory test electrocardiogram baseline 16 week . Blood sample collect centralized measure HbA1C fasting serum insulin ( FSI ) 、PSI1/2、PSI2 overnight fast patient , Body weight , supine stand blood pressure heart rate measure clinical visit . Adverse event rat mild , moderate severe investigator assess causal relationship study drug . Patients entitle interrupt treatment time study , investigator withdraw patient , particular inadequately control .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Benfluorex</mesh_term>
	<mesh_term>Fenfluramine</mesh_term>
	<criteria>For inclusion study , participant be；① Antidiabetic drug naïve Type 2 diabetes mellitus（WHO standard） diet control 2 week ; ②or diagnose Type 2 diabetes mellitus oral antidiabetic drug 6months ; ③or Type 2 diabetes mellitus treat insulin secretagogues 1 month ; patient HbA1c 7.010.0 % fast glucose 7.0mmol/L～13.0mmol/L . Ages Eligible Study : 18 Years 70 Years , Genders : Both BMI : 23～40kg/m2 No use insulin 3 month Consent birth control Women childbearing age Volunteer join sign Information consent form Patients ketoacidosis、hyperglycemic hyperosmolar syndrome . Patients severe diabetic complication Patient acute cardiovascular diseases，acute cerebrovascular diseases，with Vitamin B12、folic acid iron deficiency，with severe trauma surgery，severe infection disease . Allergy benfluorex metformin ALT、AST &gt; 2 time upper normal limit，Cr &gt; upper normal limit . Having use benfluorex within 3 month recruit . Patients accept steroid hormone malignant tumor treatment Patients drug abuse bibulous history . Patients severe unconscious low blood glucose history，severe mental illness history family history Severe hypertensive patients（SBP &gt; 160 mmHg，DBP &gt; 95mmHg） Patient pancreas disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>Benfluorex</keyword>
	<keyword>Metformin</keyword>
	<keyword>insulin secretion</keyword>
	<keyword>glucose control</keyword>
</DOC>